作者
Matteo Lambertini, Marcello Ceppi, Francesca Poggio, Fedro Alessandro Peccatori, HA Azim Jr, Donatella Ugolini, Paolo Pronzato, Sibylle Loibl, Halle CF Moore, AH Partridge, Paolo Bruzzi, Lucia Del Mastro
发表日期
2015/12/1
来源
Annals of Oncology
卷号
26
期号
12
页码范围
2408-2419
出版商
Elsevier
简介
Background
The role of temporary ovarian suppression with luteinizing hormone-releasing hormone agonists (LHRHa) in the prevention of chemotherapy-induced premature ovarian failure (POF) is still controversial. Our meta-analysis of randomized, controlled trials (RCTs) investigates whether the use of LHRHa during chemotherapy in premenopausal breast cancer patients reduces treatment-related POF rate, increases pregnancy rate, and impacts disease-free survival (DFS).
Methods
A literature search using PubMed, Embase, and the Cochrane Library, and the proceedings of major conferences, was conducted up to 30 April 2015. Odds ratios (ORs) and 95% confidence intervals (CIs) for POF (i.e. POF by study definition, and POF defined as amenorrhea 1 year after chemotherapy completion) and for patients with pregnancy, as well hazard ratios (HRs) and 95% CI for DFS, were calculated for each trial. Pooled …
学术搜索中的文章
M Lambertini, M Ceppi, F Poggio, FA Peccatori… - Annals of Oncology, 2015